Medical

According to Pneumagen, its Neumifil carbohydrate binding module (mCBM), which it is developing as a nasal spray for the prevention and treatment of respiratory infections, significantly reduced symptoms and weight loss in a hamster model of COVID-19. Researchers also found that Neumifill demonstrated high binding affinity for the ACE2 receptor and for the SARS-CoV-2 … [Read more...] about Pneumagen says preclinical study demonstrates the potential of Neumifil for COVID-19

Atossa Therapeutics announced that a two-week Phase 1 study evaluating the safety of two dose levels of the company's AT-301 nasal spray in healthy volunteers demonstrated that the nasal spray was safe and well tolerated. The company announced in August 2020 that it had received approval for the Phase 1 trial of AT-301, which it is developing as an at-home treatment … [Read more...] about Positive Phase 1 results for Atossa’s AT-301 nasal spray

Virpax Pharmaceuticals said that the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health has begun pre-clinical studies of Virpax's Envelta intranasal enkephalin to support an IND submission. Virpax signed a cooperative research and development agreement with NCATS in August 2020. Envelta is delivered via a single use … [Read more...] about Virpax begins pre-clinical studies of intranasal enkephalin to support IND

According to Union therapeutics, the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge have begun recruiting kidney patients for a clinical trial of Union's UNI91103 intranasal niclosamide for the prevention of COVID-19 in vulnerable patients. The PROTECT-V (PROphylaxis for vulnerable paTiEnts at risk of COVID-19 infecTion) trial is … [Read more...] about Clinical trial of intranasal niclosamide for the prevention of COVID-19 gets underway

TFF Pharmaceuticals said that in vitro testing has confirmed the efficacy of a monoclonal antibody against Ebolavirus Zaire and a recombinant vesicular stomatitis virus (rVSV) vaccine candidate against Venezuelan equine encephalitis virus formulated using the company's thin film freezing technology. According to TFF, the in vitro studies demonstrated that both the … [Read more...] about TFF Pharmaceuticals says it has formulated a dry powder mAb against Ebola and vaccine against equine encephalitis

Insmed Incorporated has announced data from a Phase 1 study of its treprostinil palmitil inhalation powder (TPIP) in healthy volunteers demonstrated that TPIP was generally safe and well tolerated and had a lower Cmax and longer half-life than Tyvaso. The study enrolled 42 subjects and evaluated doses as high as 225 µg for a repeated dose and 675 µg for a single … [Read more...] about Insmed says Phase 1 study of treprostinil palmitil inhalation powder supports once-daily dosing